|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
82,270,000 |
Market
Cap: |
247.63(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$2.67 - $32.15 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 8.1 |
Insider 6 Months : 8.1 |
Insider 3/6 Months : 16.7 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Revance Therapeutics is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. Co.'s segments are: Product, which refers to the business that includes the research, development and commercialization of its product candidates and the RHA® Collection of dermal fillers; and Service, which refers to the business that includes the development and commercialization of the OPUL Relational Commerce Platform and HintMD platform.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
30,000 |
30,000 |
30,000 |
30,000 |
Total Buy Value |
$209,400 |
$209,400 |
$209,400 |
$209,400 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
29,089 |
29,089 |
154,980 |
446,160 |
Total Sell Value |
$143,717 |
$143,717 |
$3,177,942 |
$12,719,522 |
Total People Sold |
4 |
4 |
5 |
5 |
Total Sell Transactions |
4 |
4 |
12 |
27 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Waugh Jacob |
Chief Scientific Officer |
|
2014-05-19 |
4 |
A |
$32.22 |
$805,500 |
D/D |
25,000 |
78,333 |
|
- |
|
Browne L Daniel |
CEO and President |
|
2014-05-19 |
4 |
A |
$32.22 |
$3,093,120 |
D/D |
96,000 |
166,626 |
|
- |
|
Ruegg Curtis |
EVP R&D and Tech Operations |
|
2014-05-19 |
4 |
A |
$32.22 |
$338,310 |
D/D |
10,500 |
14,106 |
|
- |
|
Silvernail Lauren P |
CFO, Seretary & EVP Corp Dev. |
|
2014-05-19 |
4 |
A |
$32.22 |
$451,080 |
D/D |
14,000 |
14,000 |
|
- |
|
Eastman Ronald W |
Director |
|
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
407,289 |
117,458 |
|
- |
|
Eastman Ronald W |
Director |
|
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,727,673 |
105,898 |
|
- |
|
Glasheen James Walter |
Director |
|
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
52,236 |
709,162 |
|
- |
|
Glasheen James Walter |
Director |
|
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
673,778 |
657,075 |
|
- |
|
Essex Woodlands Health Ventures Fund Viii-B Lp |
10% Owner |
|
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
407,289 |
117,458 |
|
- |
|
Essex Woodlands Health Ventures Fund Viii-B Lp |
10% Owner |
|
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,727,673 |
105,898 |
|
- |
|
Gardner Phyllis |
Director |
|
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
12,839 |
457,085 |
|
- |
|
Gardner Phyllis |
Director |
|
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
444,246 |
444,246 |
|
- |
|
Browne L Daniel |
CEO and President |
|
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
17,702 |
71,035 |
|
- |
|
Wooten Ronald J |
Director |
|
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
398,717 |
3,096,650 |
|
- |
|
Wooten Ronald J |
Director |
|
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
2,697,933 |
2,697,933 |
|
- |
|
Tunnicliffe Jonathan |
Director |
|
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
398,717 |
3,096,650 |
|
- |
|
Tunnicliffe Jonathan |
Director |
|
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
2,697,933 |
2,697,933 |
|
- |
|
Nq Hcif Gp, Ltd. |
10% Owner |
|
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
398,717 |
3,096,650 |
|
- |
|
Nq Hcif Gp, Ltd. |
10% Owner |
|
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
2,697,933 |
2,697,933 |
|
- |
|
Ruegg Curtis |
EVP R&D and Tech OperationsOff |
|
2014-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,606 |
|
- |
|
Waugh Jacob |
Chief Scientific OfficerOffice |
|
2014-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
53,333 |
|
- |
|
Browne L Daniel |
CEO and PresidentOfficer |
|
2014-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
53,333 |
|
- |
|
422 Records found
|
|
Page 17 of 17 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|